| Literature DB >> 28611658 |
Muhammad Ayaz1, Abdul Sadiq1, Muhammad Junaid1, Farhat Ullah1, Fazal Subhan2, Jawad Ahmed3.
Abstract
The use of essential oils (EOs) and their components is known since long in traditional medicine and aromatherapy for the management of various diseases, and is further increased in the recent times. The neuroprotective and anti-aging potentials of EOs and their possible mechanism of actions were evaluated by numerous researchers around the globe. Several clinically important EOs and their components from Nigella sativa, Acorus gramineus, Lavandula angustifolia, Eucalyptus globulus, Mentha piperita, Rosmarinus officinalis, Jasminum sambac, Piper nigrum and so many other plants are reported for neuroprotective effects. This review article was aimed to summarize the current finding on EOs tested against neurodegenerative disorders like Alzheimer disease (AD) and dementia. The effects of EOs on pathological targets of AD and dementia including amyloid deposition (Aβ), neurofibrillary tangles (NFTs), cholinergic hypofunction, oxidative stress and glutamatergic abnormalities were focused. Furthermore, effects of EOs on other neurological disorders including anxiety, depression, cognitive hypofunction epilepsy and convulsions were also evaluated in detail. In conclusion, EOs were effective on several pathological targets and have improved cognitive performance in animal models and human subjects. Thus, EOs can be developed as multi-potent agents against neurological disorders with better efficacy, safety and cost effectiveness.Entities:
Keywords: Alzheimer’s disease; BACE1; NFTs; amyloid-β; antioxidants; cholinesterase inhibitors; dementia; essential oils
Year: 2017 PMID: 28611658 PMCID: PMC5447774 DOI: 10.3389/fnagi.2017.00168
Source DB: PubMed Journal: Front Aging Neurosci ISSN: 1663-4365 Impact factor: 5.750
Figure 1Chemical structures of most abundant and therapeutically active compounds in essential oils (EOs).
Figure 2Clinically available anti-Alzheimer drugs. Donepezil, Galanthamine, Rivastigmine and Tacrine are cholinesterase inhibitors whereas, Memantine is N-methyl-d-aspartate (NMDA) receptor antagonist.
Figure 3Neuronal synthesis of acetylcholine (ACh). ACh is stored in the vesicles and subsequent to action potential they get fused with the membrane and release the ACh at neuronal junction. After their action on cholinergic receptors they are enzymatically cleaved by acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). EOs can inhibit the action of these cholinesterase’s and can restore their action for prolong time. Thus they are useful for the symptomatic management of Alzheimer disease (AD).
Summary of Neuropharmacological studies conducted on essential oils and bioactive components.
| Plant/Source | Part used | Study design | Results | References |
|---|---|---|---|---|
| Leaves, | AChE, BChE assays | ↓ AChE, BChE activity | Ayaz et al. ( | |
| Leaves | AChE, BChE assays | ↓ AChE, BChE activity | Ahmad et al. ( | |
| EOs | AChE, BChE inhibition | ↓ AChE, BChE activity | Okello et al. ( | |
| EOs | AChE, BChE inhibition | ↓ BChE activity | Loizzo et al. ( | |
| EOs | AChE inhibition assay | ↓ AChE activity | Souza et al. ( | |
| EOs | AChE, | ↓ AChE activity | Loizzo et al. ( | |
| EOs | Sustained attention Tasks | ↑ Vigilance | Shimizu et al. ( | |
| Memory tasks Locomotor tasks | ↑ Locomotor activity | Hongratanaworakit ( | ||
| Orange, Coffee, Lavender, Liquorice | EOs/Fragrance | Visual attention | ↑ Attention | Seo et al. ( |
| EOs | Topical application of EOS Aromatherapy effects on autonomic nervous system (ANS) | ↑ Blood oxygen saturation | Hongratanaworakit ( | |
| Ginger EOs | 6-gingerol | Aβ25–35 induced oxidative, | ↓ Aβ25–35 mediate cytotoxicity | Lee et al. ( |
| SuHeXiang Wan | EOs | Administration of Aβ1–42 | ↓ Aβ1–42 mediated JNK | Jeon et al. ( |
| Thymol, Carvacrol | EOS components | MWM test Aβ25–35 induce dysfunction | ↓ Cognitive hypofunction | Azizi et al. ( |
| EPM, FST Reduced glutathione Antioxidant activity | ↑ Locomotor activity | Cioanca et al. ( | ||
| EOs | Inj Aβ25–35 in CA1 region of HC, MWM task | ↑ Escape Latency | Majlessi et al. ( | |
| EOs | Antioxidant, Anti-apoptotic study | ↑ Superoxide dismutase (SOD) | Hancianu et al. ( | |
| Thyme, Clove, Basil, Eucalyptus, Cinnamon leaf, Juniper, Chamomile | EOs, Thymol, Carvacrol | Antioxidant studies | ↑ Free radicals scavenging effects | Tomaino et al. ( |
| EOs | ↓ lipid peroxidation | Candan et al. ( | ||
| EOs | Receptors binding study in dementia Sedative effects | ↓ Radioligands binding to M1, 5HT2A, H3 and GABAA receptors | Elliott et al. ( | |
| EOs, | Electrophysiological tasks CCMAI, CNPI tasks | ↓ TBPS binding to GABAA | Lin et al. ( | |
| Linalool | EPM Serum catecholamine Serum corticosterone | ↔ GABAA mediated anxiolysis | Cline et al. ( | |
| Lemon EOs | Limonene, Perillyl alcohol | passive avoidance test Open field test | ↑ Memory | Zhou et al. ( |
| EOs | Anxiety models | ↓ Anxiety | Gaydou et al. ( | |
| Silexan capsules | Lavender EOs | HAM-A total score | ↓ HAM-A sub-scores | Woelk and Schläfke ( |
| EOs | FST, | ↓ Anxiety | Chen et al. ( | |
| Safranal | PTZ induced SE model | ↓ GABAA receptors | Pathan et al. ( | |
| EOs | Animal depression model | ↓ Spontaneous activity | Oliveira et al. ( | |
| MES | ↓ Convulsions | Wahab et al. ( |
↑: Increase/activate, ↓: Decrease/inhibit, ↔: No effect/not modulate. CCMAI, Cohen–Mansfield Agitation Inventory; CNPI, Chinese Neuropsychiatric Inventory; EOs, essential oils; 5-HT, 5-hydroxytryptamine; EPM, elevated plus maze; FST, forced swimming test; HC, Hippocampus; HAM-A total score, Hamilton Anxiety Rating Scale; PTZ, pentylene tetrazole; MWM, Morris water maze.
Figure 4Schematic presentation of amyloidogenic pathway and formation of amyloid-β (Aβ) in AD. The amyloidogenic process is initiated by the enzymatic breakdown of amyloid precursor protein (APP) by beta amyloid cleaving enzyme (BACE1) called beta secretase at beta site. This is followed by catalytic cleavage of APP by gamma secretase to form non-soluble protein or Aβ. This Aβ accumulation in the neurons leading to impairment in the neurotransmission and neurodegeneration. EOs can inhibit the activity of BACE1 to hamper the Aβ load.
Figure 5The figure summarize various sources of free radicals production with special focus on Aβ as initiator of reactive oxygen species (ROS) and reactive nitrogen species (RNS). After generation, the free radicals attack membrane lipids, cellular organelles which leads to the production of mitochondrial toxins hydroxynonenal (HNE) and malondialdehyde. Oxidative stress damage membrane-bound ion-selective ATPases and stimulate calcium influx via stimulation of NMDA receptors, membrane attack complex (MAC), and ion-specific Aβ pore formation with ultimate increase in cytosolic and mitochondrial calcium load. Cellular amyloid targets cytochrome c oxidase, α-ketoglutarate and pyruvate dehydrogenase and thus cause mitochondrial DNA damage causing its fragmentation. Lipid peroxidation products enhance phosphorylation and aggregation of tau proteins which subsequently inhibit complex I. Excessive quantities of ROS and RNS are produced at complexes I and III. Further, the mitochondrial membrane potential (MMP) crumple and permeability-transition pores (ψm) opened leading to activation of caspases. Aβ also stimulate the production of stress-induced protein kinases (p38) and c-jun N-terminal kinase (JNK), in addition to p53, which stimulate apoptosis leading to cellular damage.
Figure 6Summary of the pathological targets in AD.